Myocardial sodium content in Cardiac disease study - a clinical study to determine the sodium content in the myocardium and skeletal muscle

Myocardial sodium content in Cardiac disease study - a clinical study to determine the sodium content in the myocardium and skeletal muscle - MyStIC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00010946

Enrollment

Registered

2017-03-20

Start date

2015-04-21

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers E26.0 I10

Interventions

Group 1: Measurement of the sodium content in the myocardium and the skeletal muscle in patients with primary hyperaldosteronism and observation of changes in sodium levels after PHA treatment. Compar

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: PHA patients have to present an aldosterone-renin-ratio of at least 25 or higher, as well as a positive saline infusion test. Patients with essential hypertension had a mean systolic blood pressure of 136 mmHg or higher. HC subjects had to be antihypertensive drug naïve with a mean systolic blood pressure of 135 mmHg or lower, measured by 24h ambulatory blood pressure registration.

Exclusion criteria

Exclusion criteria: - ineligible for MR imaging - known previous cardiac illness - chronic renal failure or a GFR < 30 - chronic liver diseases - systemic diseases affecting the heart or the lungs - treatment with aldosterone receptor antagonists or systemic glucocorticoids - pregnancy/nursing period

Design outcomes

Primary

Measure	Time frame
1) Detection and Quantification of the sodium content in the heart via sodium MRI in all three groups 2) Detection and Quantification of the myocardial sodium content in the PHA group prior and after a treatment (either surgery or medical treatment with a mineralocorticoid receptor antagonist)	—

Secondary

Measure	Time frame
1) Detection and Quantification of the sodium content in the calf muscle via sodium MRI in all three groups 2) Detection and Quantification of the skeletal sodium content in the PHA group prior and after a treatment (either surgery or medication with an mineralocorticoid receptor antagonist) 3) Comparison of various cardiovascular parameters regarding cardiac dimension, function (echocardiography), mass and fibrosis (MRI; late gadolinium enhancement)	—

Measure

Time frame

1) Detection and Quantification of the sodium content in the calf muscle via sodium MRI in all three groups 2) Detection and Quantification of the skeletal sodium content in the PHA group prior and after a treatment (either surgery or medication with an mineralocorticoid receptor antagonist) 3) Comparison of various cardiovascular parameters regarding cardiac dimension, function (echocardiography), mass and fibrosis (MRI; late gadolinium enhancement)

—

Countries

Germany

Contacts

Public ContactMartin Christa

Deutsches Zentrum für Herzinsuffizienz Würzburg/ Comprehensive Heart Failure Center

mystic@ukw.de0931-201-0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026